Caliper Life Sciences, Inc., a prominent player in the life sciences industry, is headquartered in the United States. Founded in the early 2000s, the company has established itself as a leader in providing innovative solutions for drug discovery and development. With a focus on preclinical imaging, microfluidics, and laboratory automation, Caliper Life Sciences offers a unique portfolio of products and services that enhance research efficiency and accuracy. The company operates primarily in North America and Europe, catering to a diverse clientele that includes pharmaceutical and biotechnology firms. Notable achievements include advancements in high-throughput screening technologies and the development of cutting-edge imaging systems. Caliper Life Sciences continues to solidify its market position through a commitment to innovation and excellence in the life sciences sector.
How does Caliper Life Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Caliper Life Sciences, Inc.'s score of 46 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Caliper Life Sciences, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Revvity, Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges from Caliper Life Sciences, it is important to note that any potential climate initiatives or targets would likely be aligned with those of its parent company, Revvity, Inc. This cascading relationship suggests that Caliper Life Sciences may adopt or follow the sustainability strategies and emissions reduction goals set forth by Revvity, Inc., although specific details are not available. In the context of the industry, companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets. As a subsidiary, Caliper Life Sciences may benefit from Revvity's initiatives in this area, but without explicit data or commitments, the company's current climate impact remains unclear.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,289,000 | 0,000,000 |
| Scope 2 | 29,844,000 | 00,000,000 |
| Scope 3 | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Caliper Life Sciences, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.